Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
A 47-year-old man with newly diagnosed acute myeloblastic leukemia and non-insulin-dependent diabetes mellitus developed Trichosporon asahii fungemia while receiving caspofungin as empirical antifungal therapy. The diagnosis was based on repeated isolation of T. asahii in culture of blood for three...
| Publicado en: | Infection Vol. 36; no. 1; pp. 68 - 71 |
|---|---|
| Autores principales: | , , , , |
| Formato: | case study pictorial Journal Article |
| Publicado: |
Springer Nature
Feb2008
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105658331&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105658331 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 03008126 NXO jtl: Infection issn: 03008126 maglogo: N pubinfo: dt: Feb2008 vid: 36 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105658331 2009808389 10.1007/s15010-007-6278-6 NLM17882360 105658331 ppf: 68 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. aug: au: Bayramoglu G Sonmez M Tosun I Aydin K Aydin F affil: Dept. of Microbiology and Clinical Microbiology, Karadeniz Technical University, School of Medicine, 6180 Trabzon, Turkey; gulcinbay@hotmail.com. sug: subj: Antifungal Agents Therapeutic Use Leukemia Drug Therapy Mycoses Classification Neutropenia Amphotericin B Diabetes Mellitus, Type 2 In Vitro Studies Leukemia Classification Male Microbiology Middle Age Mycoses Complications Mycoses Drug Therapy Mycoses Microbiology Mycoses Mortality Time Factors Middle Aged: 45-64 years Male ab: A 47-year-old man with newly diagnosed acute myeloblastic leukemia and non-insulin-dependent diabetes mellitus developed Trichosporon asahii fungemia while receiving caspofungin as empirical antifungal therapy. The diagnosis was based on repeated isolation of T. asahii in culture of blood for three times. Despite treatment with amphotericin B and voriconazole, the patient died. The in vitro antifungal susceptibilities of the T. asahii isolates were only available after the patient died. In vitro antifungal susceptibility tests showed high caspofungin and amphotericin B minimal inhibitory concentrations (MICs) value for this Trichosporon strain (MICs, 16 mug/ml, and > 32 mug/ml, respectively). Fluconazole, itraconazole, and voriconazole exhibited low MICs in vitro (MICs, 4 mug/ml, 0.5 mug/ml, and </= 0.015 mug/ml, respectively). Our experience strongly suggest that identification and antifungal susceptibility testing for T. asahii in neutropenic patients who may develop signs of infection in the presence of caspofungin as well as broadspectrum antibiotics treatment should not be overlooked. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|